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ABSTRACT
    Idiopathic nephrotic syndrome (INS) is the most glomerular disease that occurred in childhood with high rate
morbidity.  Glucocorticoid  is  drug  of  choice  for  INS and  responsiveness  to  this  drug  determined  prognosis.
Glucocorticoid upregulate transcription of anti-inflammatory cytokines such as IL-4 and IL-10. IL-10 is an anti-
inflammatory cytokine and has multiple role in immune response include modulate Th1/Th2 response. Vitamin
D3 interact  with  glucocorticoid  signaling.  Administered  active  form of  vitamin D3 increase  dexamethasone-
induced IL-10 expression by regulatory T cells in steroid resistant asthmatic patient. Here we showed increase of
CD4+IL10+ expression after treatment both prednisone only and combination prednison with vitamin D3. Both in
new-onset NS or rare relaps NS, combination treatment prednisone + vitamin D3 increase CD4+IL10+ expression
significantly  compared  to  prednisone-only  treated  group (p=  0.003),  which  first  group  (new-onset  nephrotic
syndrome  +  prednisone  and  vitamin  D3  treatment)  showed  the  most  CD4 +IL10+ expression  enhancement
(9.53±3.89). However this study failed to show a correlation between CD4+IL-10+ expression after prednisone and
vitamin D3 treatment with clinical outcome (linear regression test, p= 0,125). This study also showed that there
was a  no correlation between CD4+IL-10+ expression and CD3+GR expression after  prednison + vitamin D3
treatment (p= 0.088). CD4+IL-10+expression in new-onset and rarely relapsing nephrotic syndrome patients higher
in prednisone + vitamin D3 treated group than prednisone-only treated group. There is no correlation between
CD4+IL-10+expression and CD3+GR expression nor CD4+IL-10+expression and clinical outcome.
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Idiopathic  nephrotic  syndrome (INS) is  the most
glomerular disease occurred in childhood, account for
85% from all children with nephrotic syndrome [1, 2].
Annual  incidence  of  nephrotic  syndrome  in  healthy
children is estimated 2 to 7 cases per 100,000 children
younger than 18 years of age. The peak age of onset
occurs at 2 to 3 years, and approximately 50% of af -
fected children are ages 1 to 4 years; 75% are younger
than age 10 years [3]. Hospitalization rate of INS in dr
Saiful Anwar Hospital, Malang, Indonesia from Janu-
ary  2002  until  Desember  2006  was  101  cases  (34%
from 297 cases in nephrologic inpatient wards) [4].
Mechanism  that  underlying  pathogenesis  of
nephrotic  syndrome  is  still  unclear.  Nephrotic  syn-
drome  is  mediated  by  immunologic  abnormalities.
There is an evidence that nephrotic syndrome caused
by circulating factor, T-cell associated, which can cause
podocyte disfunction lead to massive proteinuria [5].
Some evidence showed association between INS (pri-
mary immunologic impairment) and imbalance of Th1
and  Th2 subtype as  immunoregulator  [1,  6,  7].   In
vitro  study  using  peripheral  blood  mononuclear  cell
(PBMC) isolated  from INS patients  showed increase
level of various cytokines such as Interleukin (IL)-1 IL-
2, IL-4 and tumor necrosis factor (TNF)-α, compared
to  control  group  or  INS  patients  at  remission  state
group.  Other  study using PBMC from patients  with
INS showed decrease of IL-10 serum level and increase
of IL-12 and IL-18 serum level  compared to control
group [8].
Glucocorticoid is  drug of choice for INS and re-
sponsiveness  to  this  drug  determined  prognosis  [9].
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Approximately  85%-90%  patients  with  INS  have  a
good  response  to  glucocorticoid  therapy  and  remit
completely from proteinuria, otherwise 10%-15% have
a partial or no response to glucocorticoid treatment [9,
10].  The mechanism underlying  unresponsiveness  to
glucocorticoid  treatment  is  complex.  It  based  on
physiologic process that involved in glucocorticoid sig-
naling. Glucocorticoid bind to cytoplasmic glucocorti-
coid  receptor  (GR),  and  then  translocate  to  nucleus
and regulate transcription process of several protein in-
clude  cytokines  [10-13].  Glucocorticoid  downregulate
transcription of pro-inflammatory cytokines such as IL-
1,  IL-2,  IL-6,  IL-8,  IL-11,  IL-12,  TNF-α,  Interferon
gamma  (IFN)-γ, granulocyte-macrophage  colony
stimulating factor (GM-CSF) and upregulate transcrip-
tion of anti-inflammatory cytokines as IL-4 and IL-10
[14].
Interleukin-10 is an anti-inflammatory cytokine and
has multiple role in immune response include modu-
late  Th1/Th2 response  via  APC (Antigen Presenting
Cells)  and directly  inhibit  proliferation and cytokine
synthesis by T cells [15-17]. In steroid resistant asth-
matic  patient,  IL-10  increase  GR  expression  via  T
CD4+ cells.  Ligand–induced GR downregulation can
be reserved by vitamin D3. Vitamin D3 interact with
glucocorticoid signaling.  Administered active form of
vitamin D3 increase dexamethasone-induced IL-10 ex-
pression by regulatory T cells in steroid resistant asth-
matic patient. Pre-incubation T cell with IL-10 and vi-
tamin D3 can improve impairment IL-10 release from
T cell that induced by dexamethasone [18].
Active  form of  vitamin  D3,  1,25(OH)2-dihydrox-
yvitamin D3, not only has a role in calcium metabo-
lism but also modulate immune response [19]. Terrier,
et al. showed that vitamin D was safe and induced de-
crease of memory B cells, increase Treg and decrease
Th1 and Th17 effector cells [20]. In vitro study of T
CD4+ cell culture conducted by Urry, et al. showed that
active  form  of  vitamin  D3  increased  population  of
CD4+IL-10+ and CD4+Foxp3+cells [21].
This current study aimed to compare the effect of
combination therapy of corticosteroid (prednisone) and
vitamin  D3  with  corticosteroid-only  therapy  on
CD4+IL-10+expression. This study also investigate the
correlation between CD4+IL-10+ and CD3+GR expres-
sion,  CD4+IL-10+ expression  and  clinical  outcome
(steroid  resistant  or  steroid  sensitive  nephrotic  syn-
drome). We hypothesized that combination therapy in-
crease  CD4+IL-10+  expression  more  than  prednisone-
only treated group both in new-onset nephrotic syn-
drome and rare relaps  nephrotic  syndrome. We also
hypothesized  that  there  is  a  correlation  between
CD4+IL-10+ expression and CD3+GR expression as well
as clinical outcome.
Study Design 
This experimental study was conducted in pediatric
nephrology  policlinic  and  pediatric  nephrology  inpa-
tient ward at dr. Saiful Anwar Hospital,  Malang, In-
donesia between October 2013 and April 2014. During
this  period 24  children  in  the  age  group 4-12 years
with new onset idiopathic nephrotic syndrome (INS)
were prospectively studied. Design of this study was an
experimental study with randomized clinical trial, dou-
ble blind, pre and post test control group. Blood sam-
ples (GR assays and IL-10 assay) obtained two times
(before and after treatment). 24 patients divided into 4
groups  consist  of  new  onset  INS  that  treated  with
prednisone  only  as  a  first  group,  new onset  of  INS
treated  with  combination of  prednisone  and vitamin
D3 as  a  second group,  rare  relaps  INS treated  with
prednisone only as the third  group, and rare relaps
INS treated with combination of prednisone and vita-
min  D3 as  the  forth  group.   Prednisone  was  given
orally at dose 2 mg/kg/day for 4 weeks. Vitamin D3
(D-Vit,  GraciaPharmindo)  also  given  orally  at  dose
2000 IU for 4 weeks. This study had been approved by
Ethical  Committee  of  dr.  Saiful  Anwar  Hospital
Malang, Indonesia. 
Patients
Blood samples were obtained from 24 patients (19
males, 31 females, aged 4-12 years) with nephrotic syn-
drome and had received treatment both in nephrology
polyclinic  and  inpatient  ward  during  experimental
study.  Inclusion  criteria  include:  diagnosed  as  idio-
pathic nephrotic syndrome (classified as first diagnosed
and intermittent relapse), age range between 1-14 years
old, approved by parents to participate in this study.
Exclusion  criteria  for  this  study:  secondary  and
congenital  nephrotic  syndrome,  frequent  relapse
nephrotic  syndrome,  and steroid resistance  nephrotic
syndrome. Subjects that met the inclusion criteria ran-
domized using randomization table.
PBMC Isolation 
Blood sample  transferred  from collection vacuum
tubes (previously mixed with anticoagulant EDTA) to
a 50 mL tube. An equal volume of PBS was added and
sample was mixed by repeated pipetting. The second
50  mL  tube  was  prepared  and   filled  with  Ficoll-
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Hipaque (d=1.077 g/mL). This Ficoll-Hipaque solution
carefully layer with the diluted blood with equal vol-
ume and then centrifuged at 1000 rpm for 30 minutes.
PBMC layer  was  removed  (second  layer)  using  mi-
cropipette and transfered to a new 15 mL centrifuge
tube. After washing two times using PBS 10 mL and
centrifuge at 1200 rpm for 10 minutes, decant the su-
pernatant and re-suspend the cell pellet in appropriate
volume of PBS. 
Assay for CD3+GR Expression 
Phycoerythrin  (PE)-labelled  antihuman  CD357
(GITR) (antibody cat# 311604,  Biolegend,  USA) and
FITC-labelled anti-human CD3 (antibody cat# 344804,
Biolegend,  USA) were  used  for  intracelullar  staining
(flowcytometry).   T  cell  lymphocyte  added  with  cell
staining buffer (2% fetal bovine serum in PBS). Five µl
pellet from PBMC isolation was taken and ready for
staining using FITC-labelled  anti-human CD3.  50 µl
diluted antibody was taken and mixed with T cell lym-
phocyte and then incubated for 20 minutes (in dark
room temperature). After this incubation, samples were
ready for GR staining. Cell were washed with 500 µl
cell staining buffer, centrifuged at 4°C, 2500 rpm for 3
minutes. After removing the supernatant, T cell lym-
phocyte  washed  with  500  µl  fix  buffer  solution,
homogenized and centrifuged at 4°C, 2500 rpm for 3
minutes. Supernatant were removed, T cell lymphocyte
fixed with 500 µl fix buffer and then incubated for 20
minutes (in dark room temperature). After incubation,
samples were centrifuged at 4°C 2500 rpm for 3 min-
utes. Supernatant were removed, and then cells washed
again,  re-suspend in permeabilization buffer.  Suspen-
sions were centrifuged again at 4°C, 2500 rpm for 3
minutes.  After  removing  the  supernatant,  cells  were
ready for cell surface staining with PE-labelled anti-hu-
man CD357 (GITR) antibody (1:250).  Each solution
stained with 50 µl PE anti-human CD357 (GITR) di-
luted antibody, incubated at dark room for 20 minutes,
and then washed with  500 µl  permeabilization wash
buffer solution. After centrifugation at 4°C, 2500 rpm
for 3 minutes,  supernatant were removed and added
with 350 µl cell staining buffer. Cell samples were run
on FACS Calibur flowcytometer and analyzed by BD
Cell Quest Pro software.
Assay for CD4+IL-10+ Expression 
PerCP/Cy5.5-labelled  anti-human  IL-10  (cat#
501418,  Biolegend,  USA)  and  FITC-labelled  anti-hu-
man CD4 antibody (cat# 300506, Biolegend,USA) in-
tracellular  staining  (flowcytometry).  T  lymphocytes
CD4+ added with cell staining buffer (2% fetal bovine
serum in PBS). Five µl pellet from PBMC isolation was
taken and ready for staining using FITC-labelled anti-
human CD4.  50  µl  diluted  antibody was  taken  and
mixed with T cell lymphocyte and then incubated for
20 minutes (in dark room temperature). After this in-
cubation,  sample  was  ready  for  IL-10  intracellular
staining. Cells  were washed with 500 µl cell  staining
buffer, centrifuged at 4°C, 2500 rpm for 3 minutes. Af-
ter  removing  the  supernatant,  T  lymphocytes  CD4+
washed with 500 µl fix buffer solution, homogenized
and centrifuged at 4°C, 2500 rpm for 3 minutes. Super-
natant were removed, T lymphocytes CD4+ fixed with
500 µl fix buffer and then incubated for 20 minutes
(dark,  room temperature).  After  incubation,  samples
were centrifuged at 4°C, 2500 rpm for 3 minutes. Su-
pernatant were removed, and then cells washed again,
re-suspend  in  permeabilization  buffer.  Suspensions
were centrifuged again at 4°C, 2500 rpm for 3 minutes.
After  removing the supernatant,  cells  were ready for
staining with PerCP/Cy5.5-labelled anti-human IL-10
antibody  (1:250).  Each  solution  stained  with  50  µl
PerCP/Cy5.5 anti-human IL-10 diluted antibody, incu-
bated at dark room for 20 minutes, and then washed
with 500 µl permeabilization wash buffer solution After
centrifugation at 4°C, 2500 rpm for 3 minutes, super-
natant were removed and added with 350 µl cell stain-
ing buffer.  Cell  samples  were run on FACS Calibur
flow cytometer  and analyzed by BD Cell  Quest  Pro
software.
Statistical Analysis
The normality of distribution was confirmed by the
Saphiro-Wilk’sW-test (normal distribution assumed as
Sig or p>0.05). The difference in IL-10 expression in
particular  lymphocyte  subpopulations  between  pred-
nisone-only and combination of prednisone and vita-
min D3 treated group confirmed by one-way ANOVA
(Kruskal-Wallis test as an alternative test). The difer-
ence  in  IL-10  expression  before  and  after  treatment
confirmed by paired t-test (Wilcoxon test as an alterna-
tive). Correlation between IL-10 expression with out-
come and GR expression among patients that given vi-
tamin D3 as adjuvant (steroid sensitive or steroid resis-
tant nephrotic syndrome) confirmed by regression test.
Data  were  analyzed  using  SPSS  for  Windows  17.0.
(confidence interval 95%). 
 
This study involved 24 patients age ranged from 4-
12 years with nephrotic syndrome (12 patient new-on-
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set  nephrotic  syndrome  and  12  patients  rare  relaps
nephrotic syndrome). Patients divided randomized into
4 treated groups. The first and second group consists
of 6 patients with new onset nephrotic syndrome. First
group treated with prednisone only, and second group
treated  with  combination of  prednisone and  vitamin
D3. The third and fourth group consists of 6 patient
with  rarery  relapsing  nephrotic  syndrome.  The third
group treated with prednisone only, and fourth group
treated  with  combination of  prednisone and  vitamin
D3.  Among all groups, there was no drop out. During
4 weeks treatment, patients were not showed any ill-
ness or adverse drug reactions caused by prednisone or
vitamin D3. 
CD4+IL10+ expression
Table 1 showed that CD4+IL10+ expression mean
in 4 groups before treatment. The differences among
groups  was  not  different  significantly  (one-way
ANOVA, p= 0.593).
There  were  significant  differences  of  CD4+IL10+
expression mean (t-test, p= 0.004) between new-onset
nephrotic syndrome before (1.99±0.73) and after treat-
ment (3.54±1.79) with prednisone. This finding showed
that  prednisone  treatment  increase  IL-10  expression
(Figure 1).
There  were  also  significant  differences  of
CD4+IL10+ expression mean (t-test, p= 0.008) between
new-onset nephrotic syndrome before (3.50±3.01) and
after treatment (9.53±3.89) that treated with combina-
tion prednisone and vitamin D3. This finding showed
that combination prednisone and vitamin D3 adminis-
tration increase IL-10 expression (Figure 2).
There  was  a  significant  difference  of  CD4+IL10+
expression mean (t-test,  p= 0.008) between rarely re-
lapsing nephrotic syndrome before (1.66±0.72) and af-
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Figure 1. CD4+IL-10+  expression before and after prednisone treatment. Upper figure represent before prednisone treatment:  A.  
CD4+ cells number stained with FITC (red) and  B. IL-10 expression on CD4+  cells stained with PerCP/Cy5.5 (green).  
Bottom figure  represent  after  prednisone  treatment):  A.  CD4+ cells  number  stained  with  FITC (red)  and  B.  IL-10  
expression on CD4+ cells stained with PerCP/Cy5.5 (green).
Table 1. Mean of CD4+IL10+ expression
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ter treatment (2.78±2.50) with prednisone. This finding
showed that  prednisone treatment  increase IL-10 ex-
pression.  There  was  also  a  significant  difference  of
CD4+IL10+ expression mean (t-test, p= 0.015) between
rarely relapsing nephrotic syndrome before (1.99±0.64)
and  after  treatment  (4.28±1.99)  with  combination of
prednisone and vitamin D3. This finding showed that
combination of prednisone and vitamin D3 treatment
increase IL-10 expression.
Figure 3 showed increase of CD4+IL10+ expression
after treatment both prednisone only or combination
prednisone  with  vitamin  D3.  Before  treatment,
CD4+IL10+ expression  in  3  groups  (new-onset
nephrotic  syndrome  treated  with  prednisone  only
group,  rarely  relapsing  nephrotic  syndrome  treated
with prednisone only group, rarely relapsing nephrotic
syndrome treated with combination of  prednisone and
vitamin D3) were almost similar. However, in new-on-
set nephrotic syndrome treated with prednisone and vi-
tamin D3, CD4+IL10+ expression was higher than other
groups. It means the first group (new-onset nephrotic
syndrome treated with combination of prednisone and
vitamin D3)  showed the most  CD4+IL10+ expression
enhancement. 
This study showed that CD4+IL10+ expression af-
ter  treatment  in  4  groups  were  statistically  different
(one-way  ANOVA,  p=  0.003)  Post-Hoc  test  showed
that there was a significant different of CD4+IL10+ ex-
pression between first group (new-onset nephrotic syn-
drome treated with combination of  prednisone and vi-
tamin  D3)  and  second  group  (new-onset  nephrotic
syndrome treated with prednisone only).   There was
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Figure 3. CD4+IL10+ expression before and after treatment among the 4 groups (*p < 0.05 showed statistically different)
Figure 2. CD4+IL-10+ expression before and after prednisone + vitamin D3 treatment. Upper figure represent before prednisone + 
vitamin D3 treatment: A. CD4+ cells number stained with FITC (red) and B. IL-10 expression on CD4+ cells stained with 
PerCP/Cy5.5 (green). Bottom represent after prednisone + vitamin D3 treatment:  A. CD4+ cells number stained with  
FITC (red) and B. IL-10 expression on CD4+ cells stained with PerCP/Cy5.5 (green).
Vitamin D3 Adjuvant Treatment Stimulate Interleukin-10 Expression in Children
also a significant different of CD4+IL10+ expression be-
tween  first  group  and  third  group  (rarely  relapsing
nephrotic syndrome treated with combination of  pred-
nisone  and  vitamin  D3),  and  also  first  group  and
fourth  group  (rarely  relapsing  nephrotic  syndrome
treated with prednisone only) (Table 2). 
Correlation of CD4+IL-10+  expression and clinical out-
come
This study showed that there was no correlation
between CD4+IL-10+ expression after  prednisone and
vitamin D3 treatment with clinical outcome (linear re-
gression test, p= 0,125).
Correlation of CD4+IL-10+ expression and CD3+GR ex-
pression
This study showed that there was a no correlation
between CD4+IL-10+ expression and CD3+GR expres-
sion  after  prednison  +  vitamin  D3  treatment  (p=
0.088). 
In this study we find that there was a significant
differences  of  IL-10  expression  between  new-onset
nephrotic  syndrome  and  rare  relaps  nephrotic  syn-
drome after treatment with prednisone or prednisone +
vitamin  D3.  CD4+IL-10+ expression  increase  in  all
treated groups, but the most enhancement occurred at
first  group  (new-onset  nephrotic  syndrome  treated
with prednisone and vitamin D3). This finding means
that  treatment  with  prednisone  or  prednisone  com-
bined with adjuvant vitamin D3 has a beneficial effect
to increase CD4+IL-10+ expression, but addition of vita-
min  D3  increase  CD4+IL-10+ expression  more  than
prednisone-only treated group. 
Increase of CD4+IL-10+ expression after glucocorti-
coid  treatment  consistent  with  previous  study  con-
ducted by Barrat, et al. (2002) that showed glucocorti-
coid not only increase IL-10 production in T lympho-
cyte, but also decrease production of IL-4, IL-5 and IL-
13 in human T CD4+ cells [22]. Other study showed
that renal T CD4+ cells was the source of endogenous
IL-10 [23]. Glucocorticoid treatment not only up-regu-
late IL-10 secretion by macrophage/ dendritic cells and
Th2 cells,  but also involved in Treg proliferation, ma-
jor immunoregulatory T lymphocyte subtype that can
produce IL-10 abundantly [23]. Glucocorticoid can also
trigger IL-10 secretion by T CD4+ cells directly [24].
Other cells  that  can be  induced to produce IL-10 is
monocyte. Mozo, et al. (2004) showed that monocyte,
not T or B cells, up-regulate IL-10 production (IL-10
protein and mRNA) after treatment with physiologic
dose of dexamethasone (after 12 hour). This study sug-
gest  that  dexamethasone treatment  can induce  IL-10
production at transcriptional level [25].
CD4+IL10+ expression  increased  significantly  in
patients with new-onset nephrotic syndrome and rare
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Table 2. Post-hoc LSD analysis of CD4+IL10+expression after treatment 
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relaps nephrotic syndrome that treated using combina-
tion  of  prednisone  and  vitamin  D3 (compared  with
prednisone-only  treated  group).  This  finding  showed
that  addition  of  vitamin  D3 has  beneficial  effect  in
inducing  IL-10  expression.  Xytraxis  et  al.  (2006)
showed that active form of vitamin D3 increase level of
IL-10+ and  Foxp3+ cells  in  human  peripheral  blood
culture [18]. 
Heine,  et  al.  (2008)  demonstrated  that  calcitriol
(an active  form of  vitamin D3, 1,25(OH2)D3)  treat-
ment increase both cell number that express IL-10 and
the amount of IL-10 expression each cells [26].  Kickler
et al. (2012) showed calcitriol induce T cell population
that secrete IL-10. Active metabolite of vitamin D in-
fluence  T cell  activation mediated  by CD46 by con-
trolling the CD46 expression and T CD4+ cell and T
CD8+ cell  function.  Calcitriol  promote switching not
only by reduction of IFN-γ production, but also pro-
mote IL-10 production via CD46 co-stimulation. This
study also showed that additional calcitriol treatment
can reverse IL-10:IFN-γ ratio (increase IL-10 secretion,
decrease IFN-γ) in multiple sclerotic patient with de-
crease of IL-10 production [27].
In  vitro  study conducted  by  Allen  et  al.  (2012)
demonstrated that there was an increase of IL-10 pro-
duction by PBMC after  vitamin D treatment,  but  T
CD4+ cells  frequency  that  produced  IL-10  was  not
change significantly. Increase of IL-10 production may
be caused by vitamin D effect on monocyte, dendritic
cells, or B cells [28].
Glucocorticoid treatment not only increase IL-10
production in T lymphocyte, but also trigger Treg cells
proliferation if administered in combination with active
form of vitamin D3, 1,25(OH2)D3. Overall,  research
data  showed that  glucocorticoid-only  or combination
glucocorticoid  +  1,25(OH2)D3  potentiate  Treg  im-
munosuppressive  effect  by  increase  IL-10  production
and/or Foxp3 expression [29].
Colin et al. (2010) demonstrated 1,25(OH)2D3 in-
hibit production of TNF-α, IL-17 and IFN-γ, and in-
duce expression of IL-4, IL-5, and IL-10 in PBMC or T
CD4+ cells. Furthermore, 1,25(OH)2D3 increase differ-
entiation of T CD4+ cells which produce IL-10 in pa-
tients with multiple sclerosis and Crohn disease [30].
1,25(OH)2D3 play an important role for T lym-
phocyte proliferation and differentiation. T lymphocyte
treatment using calcitriol or its analogs inhibit secre-
tion of various pro-inflammatory cytokines from Th1,
Th9 and Th22 cells but induce anti-inflammatory cy-
tokines production from Th2 cells. Calciotropic action
of vitamin D was suggestion for vitamin D treatment
in clinical nephrology. 1,25(OH)2D3 proven has anti-
proteinuria effect and inhibit renin angiotensin aldos-
terone system (RAAS). 1,25(OH)2D3 has a beneficial
effect  in  preserve  podocyte  structural  integrity  and
functional and also suppress renin expression directly
at transcriptional level [31].
T lymphocyte treatment with 1,25(OH)2D3 cause
reduction of IL-17, IFN-γ and IL-21 level and signifi-
cantly increase gene expression in Treg cells. Treg cell
has  anti-inflammatory  role  and  control  autoimmune
disease  by  IL-10  and  TGF-β secretion.  Besides  that,
Treg  cell  can  be  induced  and  stimulated  by
1,25(OH)2D3 through indirect pathway via APC and
dendritic cells or direct pathway via endocrine effect or
intracrine  conversion  from  25(OH)D  become
1,25(OH)2D3 by Treg cells itself. 1,25(OH)2D3 has a
various  effect  on inflammation and autoimmune dis-
ease by decrease Th17 cell  population. 1,25(OH)2D3
can also influence T cell behavior, promote tolerance
through Th2 and Treg activity induction and Th1 and
Th17 cell activity suppression [31].
In  this  study,  there  was  no  correlation between
CD4+IL10+ expression and clinical outcome. This find-
ing  is  not  consistent  with  other  study  that  showed
short  term IL-10 expression could improve glomeru-
lonephritis  and  glomerulosclerosis.  Potential  mecha-
nism underlying renoprotective effect of IL-10 maybe
complex because IL-10 has a dual action. Major effects
of IL-10 are inhibit activation and effector function of
T cells, monocytes, and macrophages. IL-10 bind to its
receptor (IL-10R), which this binding can activate sev-
eral  signaling  pathway  depend  on  cell  type,  include
pathway that depend on STAT-3, NF-κB and AP-1. IL-
10 also potentially inhibit several cytokine production
such as IL-1 and TNF-α,  chemokine such as MCP-1
and RANTES in activated monocyte/ macrophage, and
also suppress MCP-1 in inflammatory cell population
(this effect  can delay monocyte/  macrophage recruit-
ment  in  renal  interstitium).  IL-10  also  inhibits  den-
dritic cell function and T cell activation [32]. However,
correlation between IL-10 expression and clinical out-
come need further investigation.
We  conclude  that  CD4+IL-10+  expression  in
nephrotic  syndrome  patient  (new-onset  and  rare  re-
lapses) were higher in prednisone + vitamin D3 treated
group than prednisone-only treated group. This study
also  concluded  that  there  is  no  correlation  between
CD4+IL-10+  expression  and  CD3+GR  expression  nor
CD4+IL-10+ expression and clinical outcome.
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